ENSURING PATIENT ACCESS: The Crucial Role of Market Access for Drugs
Ensuring Patient Access The Crucial Role of Market Access for Drugs Navigating the journey from clinical trials to market access requires a deep understanding of the European landscape. Partner Rare’s team of experts have extensive experience in designing and conducting clinical trials tailored to meet EU regulatory requirements, while simultaneously conducting market access research to […]
Navigating Gene Therapy Commercialization in Europe: A Q&A with Novartis’ Joshi Venugopal
Navigating Gene Therapy Commercialization in Europe A Q&A with Joshi Venugopal, General Manager of Gene Therapies and Rare Diseases, Europe Opinions expressed here are personal and not that of Novartis* Gene therapies hold immense promise for revolutionizing the treatment of rare diseases, offering potential cures where previously only symptom management was possible. However, the path […]
Expanding into Europe
Cracking the EMA Code Expanding into Europe Expanding a Rare Disease drug’s marketing authorization into Europe can potentially increase a company’s net worth, but it’s not a guaranteed outcome. Here’s a breakdown of the factors involved: Potential Benefits Increased Market Size Europe represents a significant market with a large population. Expanding authorization allows the company […]